Overview
- The European Commission granted EU-wide approval for Zurzuvae (zuranolone) in September 2025, marking the first authorization targeted specifically at postpartum depression.
- Clinical studies cited in reporting indicate symptom improvements can appear within about two weeks of treatment.
- The medicine must not be used during pregnancy and is not recommended during breastfeeding because transfer into breast milk cannot be excluded.
- Experts and advocates stress the drug expands options but does not replace psychotherapy, social support, or practical postpartum help.
- Postpartum depression affects an estimated 10–15% of mothers in Europe, and specialists highlight ongoing gaps in recognition and routine screening.